Target intelligence / Profile preview

Genomic DNA off-target sites with partial prime editing guide RNA (pegRNA) complementarity (pegRNA off-target sites)

Target
pegRNA off-target sites
Molecular classification
Genomic DNA, Nucleic acid
01

Overview

Genomic DNA off-target sites with partial pegRNA complementarity refer to unintended locations within the genome where prime editing components bind and exert enzymatic activity. Prime editing utilizes a prime editing guide RNA (pegRNA) consisting of a spacer sequence for targeting and a 3' extension containing a primer binding site (PBS) and a reverse transcriptase template (RTT) (Anzalone et al., 2019). Off-target effects occur when these sequences hybridize with non-target DNA regions that possess high sequence similarity, leading to unintended nicks and genetic insertions or deletions (Doman et al., 2022). While prime editing is generally considered more precise than traditional CRISPR-Cas9, these off-target sites represent a significant safety concern in the development of gene therapies. Unintended modifications at these sites can result in genotoxicity, chromosomal rearrangements, or the disruption of essential genes, potentially leading to oncogenesis (Kim et al., 2020). Consequently, rigorous screening and computational modeling are employed to identify and minimize activity at these sites during the design of therapeutic pegRNAs.

Other names
pegRNA off-targetsPrime editing off-target sitesUnintended genomic modificationsNon-specific pegRNA binding sites
02

Mechanism of action

Unintended hybridization of the pegRNA spacer or the 3' extension (primer binding site) to non-target genomic DNA sequences, which allows the Cas9 nickase-reverse transcriptase fusion protein to bind and execute unintended reverse transcription or nicking at incorrect loci (Anzalone et al., 2019; Doman et al., 2022).

03

Biological functions

Genetic information storageTemplate for transcription
04

Disease associations

CancerGenetic instabilityMutagenesis
05

Safety considerations

GenotoxicityChromosomal translocationsInsertional mutagenesisLoss of tumor suppressor functionActivation of oncogenes
06

Interacting drugs

Prime editor 2 (PE2)

3 more in the full profile.

07

Biomarkers

GUIDE-seqCIRCLE-seqDigenome-seqIn silico off-target prediction scores

Beyond the preview

Go deeper on Genomic DNA off-target sites with partial prime editing guide RNA (pegRNA) complementarity (pegRNA off-target sites).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomic DNA off-target sites with partial prime editing guide RNA (pegRNA) complementarity (pegRNA off-target sites).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call